Promises and challenges of microRNA-based treatment of multiple myeloma

Current Cancer Drug Targets

Volumn 12, Issue 7, 2012, Pages 838-846

  Tagliaferri, P ^a   Rossi, M ^a   Di Martino, M ^a   Amodio, N ^a   Leone, E ^a   Gulla A ^a   Neri, A ^c   Tassone, P ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Temple University   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Experimental therapeutics; MicroRNA; MiRNAs; Multiple myeloma; Nanotechnology; Nucleic acid delivery

Indexed keywords

ANTAGOMIR; ANTINEOPLASTIC AGENT; ATELOCOLLAGEN; BORTEZOMIB; LIPID NANOPARTICLE; LIPOSOME; MICRORNA; MICRORNA 15A; MICRORNA 16; MICRORNA 193B 365; MICRORNA 21; NANOPARTICLE; OLIGONUCLEOTIDE; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER THERAPY; COLON CARCINOMA; DRUG DELIVERY SYSTEM; DRUG TARGETING; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC REGULATION; HUMAN; IN VIVO GENE TRANSFER; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; MYELOMA CELL; NANOTECHNOLOGY; PLASMA CELL; PROSTATE TUMOR; RECEPTOR DOWN REGULATION; UPREGULATION;

ANIMALS; BONE MARROW; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA;

EID: 84866410501     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912802429355     Document Type: Article

References (62)

1. Benetatos, L.; Vartholomatos, G. Deregulated microRNAs in multiple myeloma. Cancer 2012, 118, 878-887.
2. Pichiorri, F.; De Luca, L.; Aqeilan, R. I. MicroRNAs: New players in multiple myeloma. Front. Genet. 2011, 2, 1-8.
3. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
4. Friedman, R. C.; Farh, K. K.; Burge, C. B.; Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19, 92-105.
5. Croce, C. M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10, 704-714.
6. Esquela-Kerscher, A.; Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259-269.
7. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350-355.
8. Calin, G. A.; Sevignani, C.; Dumitru, C. D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; Croce, C. M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999-3004.
9. Garzon, R.; Marcucci, G.; Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug. Discov. 2010, 9, 775-789.
10. Roccaro, A. M.; Sacco, A.; Thompson, B.; Leleu, X.; Azab, A. K.; Azab, F.; Runnels, J.; Jia, X.; Ngo, H. T.; Melhem, M. R.; Lin, C. P.; Ribatti, D.; Rollins, B. J.; Witzig, T. E.; Anderson, K. C.; Ghobrial, I. M. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009, 113, 6669-6680.
11. Pichiorri, F.; Suh, S. S.; Rocci, A.; De Luca, L.; Taccioli, C.; Santhanam, R.; Zhou, W.; Benson, D. M. Jr.; Hofmainster, C.; Alder, H.; Garofalo, M.; Di Leva, G.; Volinia, S.; Lin, H. J.; Perrotti, D.; Kuehl, M.; Aqeilan, R. I.; Palumbo, A.; Croce, C. M. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010, 18, 367-381.
12. Lee, R. C.; Feinbaum, R. L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843-854.
13. Calin, G. A.; Dumitru, C. D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C. M. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 15524-15529.
14. Zhang, J.; Jima, D. D.; Jacobs, C.; Fischer, R.; Gottwein, E.; Huang, G.; Lugar, P. L.; Lagoo, A. S.; Rizzieri, D. A.; Friedman, D. R.; Weinberg, J. B.; Lipsky, P. E.; Dave, S. S. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009, 113, 4586-4594.
15. Iorio, M. V.; Croce, C. M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009, 27, 5848-5856.
16. Lu, J.; Getz, G.; Miska, E. A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B. L.; Mak, R. H.; Ferrando, A. A.; Downing, J. R.; Jacks, T.; Horvitz, H. R.; Golub, T. R. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
17. Jima, D. D.; Zhang, J.; Jacobs, C.; Richards, K. L.; Dunphy, C. H.; Choi, W. W.; Yan Au, W.; Srivastava, G.; Czader, M. B.; Rizzieri, D. A.; Lagoo, A. S.; Lugar, P. L.; Mann, K. P.; Flowers, C. R.; Bernal-Mizrachi, L.; Naresh, K. N.; Evens, A. M.; Gordon, L. I.; Luftig, M.; Friedman, D. R.; Weinberg, J. B.; Thompson, M. A.; Gill, J. I.; Liu, Q.; How, T.; Grubor, V.; Gao, Y.; Patel, A.; Wu, H.; Zhu, J.; Blobe, G. C.; Lipsky, P. E.; Chadburn, A.; Dave, S. S. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010, 116, e118-e127.
18. Salmena, L.; Poliseno, L.; Tay, Y.; Kats, L.; Pandolfi, P. P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011, 146, 353-358.
19. Eulalio, A.; Huntzinger, E.; Nishihara, T.; Rehwinkel, J.; Fauser, M.; Izaurralde, E. Deadenylation is a widespread effect of miRNA regulation. RNA 2009, 15, 21-32.
20. Eulalio, A.; Huntzinger, E.; Izaurralde, E. GW182 interaction with Argonaute is essential for miRNA-mediated translational repression and mRNA decay. Nat. Struct. Mol. Biol. 2008, 15, 346-353.
21. Eulalio, A.; Huntzinger, E.; Izaurralde, E. Getting to the root of miRNA-mediated gene silencing. Cell 2008, 132, 9-14.
22. Orom, U. A.; Nielsen, F. C.; Lund, A. H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell. 2008, 30, 460-471.
23. Eiring, A. M.; Harb, J. G.; Neviani, P.; Garton, C.; Oaks, J. J.; Spizzo, R.; Liu, S.; Schwind, S.; Santhanam, R.; Hickey, C. J.; Becker, H.; Chandler, J. C.; Andino, R.; Cortes, J.; Hokland, P.; Huettner, C. S.; Bhatia, R.; Roy, D. C.; Liebhaber, S. A.; Caligiuri, M. A.; Marcucci, G.; Garzon, R.; Croce, C. M.; Calin, G. A.; Perrotti, D. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010, 140, 652-665.
24. Khraiwesh, B.; Arif, M. A.; Seumel, G. I.; Ossowski, S.; Weigel, D.; Reski, R.; Frank, W. Transcriptional control of gene expression by microRNAs. Cell 2010, 140, 111-122.
25. Pichiorri, F.; Suh, S. S.; Ladetto, M.; Kuehl, M.; Palumbo, T.; Drandi, D.; Taccioli, C.; Zanesi, N.; Alder, H.; Hagan, J. P.; Munker, R.; Volinia, S.; Boccadoro, M.; Garzon, R.; Palumbo, A.; Aqeilan, R. I.; Croce, C. M. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. USA 2008, 105, 12885-12890.
26. Zhou, Y.; Chen, L.; Barlogie, B.; Stephens, O.; Wu, X.; Williams, D. R.; Cartron, M. A.; van Rhee, F.; Nair, B.; Waheed, S.; Pineda-Roman, M.; Alsayed, Y.; Anaissie, E.; Shaughnessy, J. D. Jr. Highrisk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc. Natl. Acad. Sci. USA 2010, 107, 7904-7909.
27. Subramanian, A.; Tamayo, P.; Mootha, V. K.; Mukherjee, S.; Ebert, B. L.; Gillette, M. A.; Paulovich, A.; Pomeroy, S. L.; Golub, T. R.; Lander, E. S.; Mesirov, J. P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545-15550.
28. Shaughnessy, J. D. Jr.; Zhan, F.; Burington, B. E.; Huang, Y.; Colla, S.; Hanamura, I.; Stewart, J. P.; Kordsmeier, B.; Randolph, C.; Williams, D. R.; Xiao, Y.; Xu, H.; Epstein, J.; Anaissie, E.; Krishna, S. G.; Cottler-Fox, M.; Hollmig, K.; Mohiuddin, A.; Pineda-Roman, M.; Tricot, G.; van Rhee, F.; Sawyer, J.; Alsayed, Y.; Walker, R.; Zangari, M.; Crowley, J.; Barlogie, B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109, 2276-2284.
29. Lionetti, M.; Biasiolo, M.; Agnelli, L.; Todoerti, K.; Mosca, L.; Fabris, S.; Sales, G.; Deliliers, G. L.; Bicciato, S.; Lombardi, L.; Bortoluzzi, S.; Neri, A. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009, 114, e20-e26.
30. Agnelli, L.; Bicciato, S.; Mattioli, M.; Fabris, S.; Intini, D.; Verdelli, D.; Baldini, L.; Morabito, F.; Callea, V.; Lombardi, L.; Neri, A. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J. Clin. Oncol. 2005, 23, 7296-7306.
31. Munker, R.; Liu, C. G.; Taccioli, C.; Alder, H.; Heerema, N. MicroRNA profiles of drug-resistant myeloma cell lines. Acta Haematol. 2010, 123, 201-204.
32. Chim, C. S.; Wong, K. Y.; Qi, Y.; Loong, F.; Lam, W. L.; Wong, L. G.; Jin, D. Y.; Costello, J. F.; Liang, R. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010, 31, 745-750.
33. Petrocca, F.; Visone, R.; Onelli, M. R.; Shah, M. H.; Nicoloso, M. S.; de Martino, I.; Iliopoulos, D.; Pilozzi, E.; Liu, C. G.; Negrini, M.; Cavazzini, L.; Volinia, S.; Alder, H.; Ruco, L. P.; Baldassarre, G.; Croce, C. M.; Vecchione, A. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13, 272-286.
34. Loffler, D.; Brocke-Heidrich, K.; Pfeifer, G.; Stocsits, C.; Hackermuller, J.; Kretzschmar, A. K.; Burger, R.; Gramatzki, M.; Blumert, C.; Bauer, K.; Cvijic, H.; Ullmann, A. K.; Stadler, P. F.; Horn, F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110, 1330-1333.
35. Unno, K.; Zhou, Y.; Zimmerman, T.; Platanias, L. C.; Wickrema, A., Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk. Lymphoma 2009, 50, 1865-1871.
36. Sarasquete, M. E.; Gutierrez, N. C.; Misiewicz-Krzeminska, I.; Paiva, B.; Chillon, M. C.; Alcoceba, M.; Garcia-Sanz, R.; Hernandez, J. M.; Gonzalez, M.; San-Miguel, J. F. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica 2011, 96, 468-471.
37. Chiosea, S.; Jelezcova, E.; Chandran, U.; Luo, J.; Mantha, G.; Sobol, R. W.; Dacic, S. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007, 67, 2345-2350.
38. Merritt, W. M.; Lin, Y. G.; Han, L. Y.; Kamat, A. A.; Spannuth, W. A.; Schmandt, R.; Urbauer, D.; Pennacchio, L. A.; Cheng, J. F.; Nick, A. M.; Deavers, M. T.; Mourad-Zeidan, A.; Wang, H.; Mueller, P.; Lenburg, M. E.; Gray, J. W.; Mok, S.; Birrer, M. J.; Lopez-Berestein, G.; Coleman, R. L.; Bar-Eli, M.; Sood, A. K. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 2008, 359, 2641-2650.
39. Farazi, T. A.; Spitzer, J. I.; Morozov, P.; Tuschl, T. MiRNAs in human cancer. J. Pathol. 2011, 223, 102-115.
40. Duchaine, T. F.; Slack, F. J. RNA interference and micro RNA - oriented therapy in cancer: rationales, promises, and challenges. Curr. Oncol. 2009, 16, 61-66.
41. Wheeler, D. L.; Dunn, E. F.; Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7, 493-507.
42. Check Hayden, E. Cancer complexity slows quest for cure. Nature 2008, 455, 148.
43. Medina, P. P.; Nolde, M.; Slack, F. J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467, 86-90.
44. Claudio, J. O.; Zhan, F.; Zhuang, L.; Khaja, R.; Zhu, Y. X.; Sivananthan, K.; Trudel, S.; Masih-Khan, E.; Fonseca, R.; Bergsagel, P. L.; Scherer, S. W.; Shaughnessy, J.; Stewart, A. K. Expression and mutation status of candidate kinases in multiple myeloma. Leukemia 2007, 21, 1124-1127.
45. Costinean, S.; Zanesi, N.; Pekarsky, Y.; Tili, E.; Volinia, S.; Heerema, N.; Croce, C. M. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl. Acad. Sci. USA 2006, 103, 7024-7029.
46. Slack, F. J.; Weidhaas, J. B. MicroRNAs as a potential magic bullet in cancer. Future Oncol. 2006, 2, 73-82.
47. Wiggins, J. F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Patrawala, L.; Brown, D.; Bader, A. G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70, 5923-5930.
48. Bader, A. G.; Brown, D.; Winkler, M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70, 7027-7030.
49. Cortez, M. A.; Bueso-Ramos, C.; Ferdin, J.; Lopez-Berestein, G.; Sood, A. K.; Calin, G. A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8, 467-477.
50. De Rosa, G.; La Rotonda, M. I., Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules 2009, 14, 2801-2823.
51. De Rosa, G.; De Stefano, D.; Galeone, A. Oligonucleotide delivery in cancer therapy. Expert. Opin. Drug. Deliv. 2010, 7, 1263-1278.
52. Trang, P.; Medina, P. P.; Wiggins, J. F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Homer, R.; Brown, D.; Bader, A. G.; Weidhaas, J. B.; Slack, F. J. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29, 1580-1587.
53. Trang, P.; Wiggins, J. F.; Daige, C. L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J. B.; Bader, A. G.; Slack, F. J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19, 1116-1122.
54. Ma, L.; Reinhardt, F.; Pan, E.; Soutschek, J.; Bhat, B.; Marcusson, E. G.; Teruya-Feldstein, J.; Bell, G. W.; Weinberg, R. A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28, 341-347.
55. Xu, D.; Takeshita, F.; Hino, Y.; Fukunaga, S.; Kudo, Y.; Tamaki, A.; Matsunaga, J.; Takahashi, R. U.; Takata, T.; Shimamoto, A.; Ochiya, T.; Tahara, H. MiR-22 represses cancer progression by inducing cellular senescence. J. Cell. Biol. 2011, 193, 409-424.
56. Wu, Y.; Crawford, M.; Yu, B.; Mao, Y.; Nana-Sinkam, S. P.; Lee, L. J. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 2011, 8, 1381-1389.
57. Ibrahim, A. F.; Weirauch, U.; Thomas, M.; Grunweller, A.; Hartmann, R. K.; Aigner, A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011, 71, 5214-5224.
58. Takeshita, F.; Patrawala, L.; Osaki, M.; Takahashi, R. U.; Yamamoto, Y.; Kosaka, N.; Kawamata, M.; Kelnar, K.; Bader, A. G.; Brown, D.; Ochiya, T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010, 18, 181-187.
59. Zhang, R.; Wang, L.; Yu, G. R.; Zhang, X.; Yao, L. B.; Yang, A. G. MicroRNA-122 might be a double-edged sword in hepatocellular carcinoma. Hepatology 2009, 50, 1322-1323.
60. Chi, J.; Ballabio, E.; Chen, X. H.; Kusec, R.; Taylor, S.; Hay, D.; Tramonti, D.; Saunders, N. J.; Littlewood, T.; Pezzella, F.; Boultwood, J.; Wainscoat, J. S.; Hatton, C. S.; Lawrie, C. H. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol. Direct. 2011, 6, 23.
61. Calimeri, T.; Battista, E.; Conforti, F.; Neri, P.; Di Martino, M. T.; Rossi, M.; Foresta, U.; Piro, E.; Ferrara, F.; Amorosi, A.; Bahlis, N.; Anderson, K. C.; Munshi, N.; Tagliaferri, P.; Causa, F.; Tassone, P. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011, 25, 707-711.
62. Anton, R.; Chatterjee, S. S.; Simundza, J.; Cowin, P.; Dasgupta, R. A Systematic Screen for Micro-RNAs Regulating the Canonical Wnt Pathway. PLoS One 2011, 6, e26257.